{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T01:36:55Z","timestamp":1783388215106,"version":"3.54.6"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2016,9,28]],"date-time":"2016-09-28T00:00:00Z","timestamp":1475020800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Novartis Pharma AG"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1007\/s40266-016-0405-y","type":"journal-article","created":{"date-parts":[[2016,9,28]],"date-time":"2016-09-28T09:47:57Z","timestamp":1475056077000},"page":"725-736","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Effects of Renal Impairment on Steady-State Plasma Concentrations of Rivastigmine: A Population Pharmacokinetic Analysis of Capsule and Patch Formulations in Patients with Alzheimer\u2019s Disease"],"prefix":"10.1007","volume":"33","author":[{"given":"Gilbert","family":"Lef\u00e8vre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Callegari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Gsteiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,9,28]]},"reference":[{"key":"405_CR1","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/GIM.0b013e31816b64dc","volume":"10","author":"TD Bird","year":"2008","unstructured":"Bird TD. Genetic aspects of Alzheimer disease. Genet Med. 2008;10:231\u20139.","journal-title":"Genet Med."},{"key":"405_CR2","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3174\/ajnr.A3545","volume":"35","author":"AT Rao","year":"2014","unstructured":"Rao AT, Degnan AJ, Levy LM. Genetics of Alzheimer disease. AJNR Am J Neuroradiol. 2014;35:457\u20138.","journal-title":"AJNR Am J Neuroradiol."},{"key":"405_CR3","first-page":"24","volume":"42","author":"JS Bell","year":"2013","unstructured":"Bell JS, Blacker N, Leblanc VT, Alderman CP, Phillips A, Rowett D, et al. Prescribing for older people with chronic renal impairment. Aust Fam Physician. 2013;42:24\u20138.","journal-title":"Aust Fam Physician."},{"key":"405_CR4","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/geronj\/31.2.155","volume":"31","author":"JW Rowe","year":"1976","unstructured":"Rowe JW, Andres R, Tobin JD, Norris AH, Shock NW. The effect of age on creatinine clearance in men: a cross-sectional and longitudinal study. J Gerontol. 1976;31:155\u201363.","journal-title":"J Gerontol."},{"key":"405_CR5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/01.NEP.0000361312.27730.cc","volume":"9","author":"RJ Glassock","year":"2009","unstructured":"Glassock RJ. The GFR decline with aging: a sign of normal senescence, not disease. Nephrol Times. 2009;9:6\u20138.","journal-title":"Nephrol Times."},{"issue":"4","key":"405_CR6","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1159\/000008243","volume":"44","author":"M Farlow","year":"2000","unstructured":"Farlow M, Anand R, Messina J Jr, Hartman R, Veach J. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer\u2019s disease. Eur Neurol. 2000;44(4):236\u201341.","journal-title":"Eur Neurol."},{"key":"405_CR7","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1136\/bmj.318.7184.633","volume":"318","author":"M Rosler","year":"1999","unstructured":"Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, et al. Efficacy and safety of rivastigmine in patients with Alzheimer\u2019s disease: international randomised controlled trial. BMJ. 1999;318:633\u20138.","journal-title":"BMJ."},{"key":"405_CR8","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000080972","volume":"19","author":"Y Karaman","year":"2005","unstructured":"Karaman Y, Erdogan F, Koseoglu E, Turan T, Ozdemir Ersoy A. A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer\u2019s disease. Dement Geriatr Cogn Disord. 2005;19:51\u20136.","journal-title":"Dement Geriatr Cogn Disord."},{"key":"405_CR9","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa041470","volume":"351","author":"M Emre","year":"2004","unstructured":"Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, et al. Rivastigmine for dementia associated with Parkinson\u2019s disease. N Engl J Med. 2004;351:2509\u201318.","journal-title":"N Engl J Med."},{"key":"405_CR10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2147\/ciia.2007.2.1.17","volume":"2","author":"ML Onor","year":"2007","unstructured":"Onor ML, Trevisiol M, Aguglia E. Rivastigmine in the treatment of Alzheimer\u2019s disease: an update. Clin Interv Aging. 2007;2:17\u201332.","journal-title":"Clin Interv Aging."},{"key":"405_CR11","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/S0149-2918(04)90172-5","volume":"26","author":"SI Finkel","year":"2004","unstructured":"Finkel SI. Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer\u2019s disease. Clin Ther. 2004;26:980\u201390.","journal-title":"Clin Ther."},{"key":"405_CR12","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1177\/1533317510365344","volume":"25","author":"MR Farlow","year":"2010","unstructured":"Farlow MR, Cummings JL, Olin JT, Meng X. Effects of oral rivastigmine on cognitive domains in mild-to-moderate Alzheimer\u2019s disease. Am J Alzheimers Dis Other Demen. 2010;25:347\u201352.","journal-title":"Am J Alzheimers Dis Other Demen."},{"key":"405_CR13","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/gps.1058","volume":"19","author":"A Burns","year":"2004","unstructured":"Burns A, Spiegel R, Quarg P. Efficacy of rivastigmine in subjects with moderately severe Alzheimer\u2019s disease. Int J Geriatr Psychiatry. 2004;19:243\u20139.","journal-title":"Int J Geriatr Psychiatry."},{"key":"405_CR14","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1600-0404.1998.tb00645.x","volume":"97","author":"NR Cutler","year":"1998","unstructured":"Cutler NR, Polinsky RJ, Sramek JJ, Enz A, Jhee SS, Mancione L, et al. Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer\u2019s disease. Acta Neurol Scand. 1998;97:244\u201350.","journal-title":"Acta Neurol Scand."},{"key":"405_CR15","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/00004714-199912000-00005","volume":"19","author":"JS Kennedy","year":"1999","unstructured":"Kennedy JS, Polinsky RJ, Johnson B, Loosen P, Enz A, Laplanche R, et al. Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans. J Clin Psychopharmacol. 1999;19:513\u201321.","journal-title":"J Clin Psychopharmacol."},{"key":"405_CR16","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1177\/0091270008330161","volume":"49","author":"G Lef\u00e8vre","year":"2009","unstructured":"Lef\u00e8vre G, Buche M, Sedek G, Maton S, Enz A, Lorch U, et al. Similar rivastigmine pharmacokinetics and pharmacodynamics in Japanese and white healthy participants following the application of novel rivastigmine patch. J Clin Pharmacol. 2009;49:430\u201343.","journal-title":"J Clin Pharmacol."},{"key":"405_CR17","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2165\/00002512-199813050-00005","volume":"13","author":"CM Spencer","year":"1998","unstructured":"Spencer CM, Noble S. Rivastigmine: a review of its use in Alzheimer\u2019s disease. Drugs Aging. 1998;13:391\u2013411.","journal-title":"Drugs Aging."},{"key":"405_CR18","unstructured":"US Food and Drug Administration. Guidance for Industry. Pharmacokinetics in patients with impaired renal function\u2014study design, data analysis, and impact on dosing and labeling. 2010. http:\/\/www.fda.gov\/downloads\/Drugs\/\u2026\/Guidances\/UCM204959.pdf . Accessed 2 Nov 2015."},{"key":"405_CR19","unstructured":"US Food and Drug Administration. Guidance for Industry. Population pharmacokinetics. 1999. http:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/UCM072137.pdf . Accessed 2 Nov 2015."},{"key":"405_CR20","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1177\/0091270007312154","volume":"48","author":"G Lef\u00e8vre","year":"2008","unstructured":"Lef\u00e8vre G, Pommier F, Sedek G, Allison M, Huang HL, Kiese B, et al. Pharmacokinetics and bioavailability of the novel rivastigmine transdermal patch versus rivastigmine oral solution in healthy elderly subjects. J Clin Pharmacol. 2008;48:246\u201352.","journal-title":"J Clin Pharmacol."},{"key":"405_CR21","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/gps.1788","volume":"22","author":"B Winblad","year":"2007","unstructured":"Winblad B, Cummings J, Andreasen N, Grossberg G, Onofrj M, Sadowsky C, et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer\u2019s disease\u2013rivastigmine patch versus capsule. Int J Geriatr Psychiatry. 2007;22:456\u201367.","journal-title":"Int J Geriatr Psychiatry."},{"issue":"4 Suppl 1","key":"405_CR22","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1212\/01.wnl.0000281847.17519.e0","volume":"69","author":"B Winblad","year":"2007","unstructured":"Winblad B, Grossberg G, Frolich L, Farlow M, Zechner S, Nagel J, et al. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology. 2007;69(4 Suppl 1):S14\u201322.","journal-title":"Neurology."},{"key":"405_CR23","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S1570-0232(02)00816-4","volume":"784","author":"F Pommier","year":"2003","unstructured":"Pommier F, Frigola R. Quantitative determination of rivastigmine and its major metabolite in human plasma by liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry. J Chromatogr B. 2003;784:301\u201313.","journal-title":"J Chromatogr B."},{"key":"405_CR24","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31\u201341.","journal-title":"Nephron."},{"key":"405_CR25","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604\u201312.","journal-title":"Ann Intern Med."},{"key":"405_CR26","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMra054415","volume":"354","author":"LA Stevens","year":"2006","unstructured":"Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function\u2013measured and estimated glomerular filtration rate. N Engl J Med. 2006;354:2473\u201383.","journal-title":"N Engl J Med."},{"key":"405_CR27","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2147\/CIA.S2468","volume":"3","author":"RL Bushardt","year":"2008","unstructured":"Bushardt RL, Massey EB, Simpson TW, Ariail JC, Simpson KN. Polypharmacy: misleading, but manageable. Clin Interv Aging. 2008;3:383\u20139.","journal-title":"Clin Interv Aging."},{"key":"405_CR28","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1447-0594.2011.00737.x","volume":"12","author":"TY Yong","year":"2012","unstructured":"Yong TY, Lau SY, Li JY, Hakendorf P, Thompson CH. Medication prescription among elderly patients admitted through an acute assessment. Geriatr Gerontol Int. 2012;12:93\u2013101.","journal-title":"Geriatr Gerontol Int."},{"key":"405_CR29","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/sj.clpt.6100242","volume":"83","author":"G Lef\u00e8vre","year":"2008","unstructured":"Lef\u00e8vre G, Sedek G, Jhee SS, Leibowitz MT, Huang HL, Enz A, et al. Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer\u2019s disease patients. Clin Pharmacol Ther. 2008;83:106\u201314.","journal-title":"Clin Pharmacol Ther."},{"issue":"1 Suppl","key":"405_CR30","doi-asserted-by":"crossref","first-page":"79S","DOI":"10.1177\/0091270011415410","volume":"52","author":"L Zhang","year":"2012","unstructured":"Zhang L, Xu N, Xiao S, Arya V, Zhao P, Lesko LJ, et al. Regulatory perspectives on designing pharmacokinetic studies and optimizing labeling recommendations for patients with chronic kidney disease. J Clin Pharmacol. 2012;52(1 Suppl):79S\u201390S.","journal-title":"J Clin Pharmacol."},{"key":"405_CR31","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/00003088-200241030-00006","volume":"41","author":"M Hossain","year":"2002","unstructured":"Hossain M, Jhee SS, Shiovitz T, McDonald C, Sedek G, Pommier F, et al. Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer\u2019s type. Clin Pharmacokinet. 2002;41:225\u201334.","journal-title":"Clin Pharmacokinet."},{"key":"405_CR32","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.clpt.2005.10.005","volume":"79","author":"A Periclou","year":"2006","unstructured":"Periclou A, Ventura D, Rao N, Abramowitz W. Pharmacokinetic study of memantine in healthy and renally impaired subjects. Clin Pharmacol Ther. 2006;79:134\u201343.","journal-title":"Clin Pharmacol Ther."},{"key":"405_CR33","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2174\/157488410791110805","volume":"5","author":"F Huang","year":"2010","unstructured":"Huang F, Fu Y. A review of clinical pharmacokinetics and pharmacodynamics of galantamine, a reversible acetylcholinesterase inhibitor for the treatment of Alzheimer\u2019s disease, in healthy subjects and patients. Curr Clin Pharmacol. 2010;5:115\u201324.","journal-title":"Curr Clin Pharmacol."},{"key":"405_CR34","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1046\/j.1365-2125.1998.0460s1019.x","volume":"46","author":"PJ Tiseo","year":"1998","unstructured":"Tiseo PJ, Perdomo CA, Friedhoff LT. Metabolism and elimination of 14C-donepezil in healthy volunteers: a single-dose study. Br J Clin Pharmacol. 1998;46:19\u201324.","journal-title":"Br J Clin Pharmacol."},{"key":"405_CR35","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1046\/j.1365-2125.1998.0460s1056.x","volume":"46","author":"PJ Tiseo","year":"1998","unstructured":"Tiseo PJ, Foley K, Friedhoff LT. An evaluation of the pharmacokinetics of donepezil HCl in patients with moderately to severely impaired renal function. Br J Clin Pharmacol. 1998;46:56\u201360.","journal-title":"Br J Clin Pharmacol."},{"issue":"1 Suppl","key":"405_CR36","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1365-2125.2004.01803.x","volume":"58","author":"CF Nagy","year":"2004","unstructured":"Nagy CF, Kumar D, Cullen EI, Bolton WK, Marbury TC, Gutierrez MJ, et al. Steady-state pharmacokinetics and safety of donepezil HCl in subjects with moderately impaired renal function. Br J Clin Pharmacol. 2004;58(1 Suppl):18\u201324.","journal-title":"Br J Clin Pharmacol."}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-016-0405-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40266-016-0405-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-016-0405-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T19:52:44Z","timestamp":1498333964000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40266-016-0405-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,28]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["405"],"URL":"https:\/\/doi.org\/10.1007\/s40266-016-0405-y","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,28]]}}}